Abstract
Remarkable therapeutic advances in the treatment of acute coronary syndromes (ACS) have been made with combined antithrombotic therapy. Aspirin is accepted as standard therapy in the management of ACS but has significant limitations, including intolerance, resistance, and peptic ulceration. With the intravenous platelet glycoprotein IIb/IIIa inhibitors and the new thienopyridine clopidogrel, the options for acute and chronic antiplatelet therapy have expanded. Recently, the combination of antiplatelet therapy and oral anticoagulation has gained much interest and has been shown to be effective in secondary prevention of ACS. This article summarizes important recent findings on the background of existing pathological and clinical knowledge to provide an understanding of the basis of current combined antithrombotic therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
